---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-032187"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:17:47.225224+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Interpace Q3 revenue $8.2M (+2%), adjusted EBITDA positive; going concern removed

## Summary
- Q3 revenue $8.2M, up 2% YoY; gross margin improved to 58% from 55%.
- Adjusted EBITDA positive $0.1M vs -$0.2M prior year; loss from continuing ops $1.3M.
- Cash balance $6.3M (up from $3.2M); sale of Pharma business removed going concern.
- ThyGeNEXT pricing change reduced revenue and EBITDA by ~$1.4M in Q3.
- Nine-month revenue $23.5M (-2%); loss from continuing ops improved to -$4.5M.

## SEC filing metadata
- accession: 0001493152-22-032187
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315222032187/0001493152-22-032187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315222032187/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-032187
- JSON: https://secwatch.observer/filing/0001493152-22-032187.json
- Plain text: https://secwatch.observer/filing/0001493152-22-032187.txt

## Key facts
- Earnings Releases
  INTERPACE BIOSCIENCES, INC. reported the quarter ended September 30, 2022 results: revenue $8.2 million.
  - Period: the quarter ended September 30, 2022
  - Revenue: $8.2 million
  - Result: reported results
  source text: Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern ● Q3 Revenue of $8.2 million up 2% versus Prior Year ● Q3 Adjusted EBITDA Positive ● Cash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, November 14, 2022 (GLOBE NEWSWIRE)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1054102/000149315222032187/0001493152-22-032187-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.